Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Adjuvant oxaliplatin plus oral capecitabine (XELOX) is recommended for patients with curatively resected colon cancer. However, its safety and tolerability in Asian patients is unclear; therefore, we evaluated the safety and efficacy of adjuvant XELOX in Japanese patients with curatively resected stage III colon cancer (MCSCO-1024) and present the interim safety data. Methods: This prospective, multi-center, open-label, single-arm phase II study recruited patients with curatively resected stage III colon cancer. The protocol was a 120-min intravenous infusion of oxaliplatin (130 mg/m2) on day 1 and oral capecitabine (2000 mg/m2/day) in two divided doses for 14 days of a 3-week cycle, for a total of eight cycles (24 weeks). The primary endpoint was the 3-year disease-free survival, and secondary endpoints were the treatment completion rate, safety profile (rate and severity of adverse events), and correlation of adverse events, such as peripheral sensory neuropathy (PSN), with the administration period of oxaliplatin, etc. Results: From November 2011 to August 2014 (34 months), 196 patients were enrolled. Safety was analyzed in 190 patients. The median total doses of capecitabine and oxaliplatin were 215,586.9 and 777.2 mg/m2, respectively, while the median relative dose intensities were 82.5 and 76.0%, respectively. The overall treatment completion rate was 73.7%. The most frequent treatment-related adverse event was PSN (88.4%), while the most frequent grade ≥3 treatment-related adverse events were neutropenia (12.6%), PSN (6.3%), diarrhea (4.2%), and thrombocytopenia (4.2%). There were no treatment-related deaths. Conclusions: Adjuvant XELOX is tolerable for Japanese patients with Stage III colon cancer.

Original languageEnglish
Pages (from-to)777-785
Number of pages9
JournalCancer chemotherapy and pharmacology
Volume80
Issue number4
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

oxaliplatin
Colonic Neoplasms
Safety
Peripheral Nervous System Diseases
Therapeutics
Labels
Capecitabine
XELOX
Neutropenia
Intravenous Infusions
Thrombocytopenia
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer. / Multi-Center Clinical Study Group of Osaka; Colorectal Cancer Treatment Group (MCSGO).

In: Cancer chemotherapy and pharmacology, Vol. 80, No. 4, 01.10.2017, p. 777-785.

Research output: Contribution to journalArticle

@article{0c404eaad8ef4805b9de9ad22cdc583c,
title = "Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer",
abstract = "Purpose: Adjuvant oxaliplatin plus oral capecitabine (XELOX) is recommended for patients with curatively resected colon cancer. However, its safety and tolerability in Asian patients is unclear; therefore, we evaluated the safety and efficacy of adjuvant XELOX in Japanese patients with curatively resected stage III colon cancer (MCSCO-1024) and present the interim safety data. Methods: This prospective, multi-center, open-label, single-arm phase II study recruited patients with curatively resected stage III colon cancer. The protocol was a 120-min intravenous infusion of oxaliplatin (130 mg/m2) on day 1 and oral capecitabine (2000 mg/m2/day) in two divided doses for 14 days of a 3-week cycle, for a total of eight cycles (24 weeks). The primary endpoint was the 3-year disease-free survival, and secondary endpoints were the treatment completion rate, safety profile (rate and severity of adverse events), and correlation of adverse events, such as peripheral sensory neuropathy (PSN), with the administration period of oxaliplatin, etc. Results: From November 2011 to August 2014 (34 months), 196 patients were enrolled. Safety was analyzed in 190 patients. The median total doses of capecitabine and oxaliplatin were 215,586.9 and 777.2 mg/m2, respectively, while the median relative dose intensities were 82.5 and 76.0{\%}, respectively. The overall treatment completion rate was 73.7{\%}. The most frequent treatment-related adverse event was PSN (88.4{\%}), while the most frequent grade ≥3 treatment-related adverse events were neutropenia (12.6{\%}), PSN (6.3{\%}), diarrhea (4.2{\%}), and thrombocytopenia (4.2{\%}). There were no treatment-related deaths. Conclusions: Adjuvant XELOX is tolerable for Japanese patients with Stage III colon cancer.",
author = "{Multi-Center Clinical Study Group of Osaka} and {Colorectal Cancer Treatment Group (MCSGO)} and Katsuki Danno and Taishi Hata and Koki Tamai and Yujiro Fujie and Yoshihito Ide and Kim, {Ho Min} and Tadashi Ohnishi and Shunji Morita and Shinichi Yoshioka and Toshihiro Kudo and Junichi Nishimura and Chu Matsuda and Hiroki Akamatsu and Tsunekazu Mizushima and Riichiro Nezu and Yuichiro Doki and Masaki Mori",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s00280-017-3419-1",
language = "English",
volume = "80",
pages = "777--785",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

AU - Multi-Center Clinical Study Group of Osaka

AU - Colorectal Cancer Treatment Group (MCSGO)

AU - Danno, Katsuki

AU - Hata, Taishi

AU - Tamai, Koki

AU - Fujie, Yujiro

AU - Ide, Yoshihito

AU - Kim, Ho Min

AU - Ohnishi, Tadashi

AU - Morita, Shunji

AU - Yoshioka, Shinichi

AU - Kudo, Toshihiro

AU - Nishimura, Junichi

AU - Matsuda, Chu

AU - Akamatsu, Hiroki

AU - Mizushima, Tsunekazu

AU - Nezu, Riichiro

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose: Adjuvant oxaliplatin plus oral capecitabine (XELOX) is recommended for patients with curatively resected colon cancer. However, its safety and tolerability in Asian patients is unclear; therefore, we evaluated the safety and efficacy of adjuvant XELOX in Japanese patients with curatively resected stage III colon cancer (MCSCO-1024) and present the interim safety data. Methods: This prospective, multi-center, open-label, single-arm phase II study recruited patients with curatively resected stage III colon cancer. The protocol was a 120-min intravenous infusion of oxaliplatin (130 mg/m2) on day 1 and oral capecitabine (2000 mg/m2/day) in two divided doses for 14 days of a 3-week cycle, for a total of eight cycles (24 weeks). The primary endpoint was the 3-year disease-free survival, and secondary endpoints were the treatment completion rate, safety profile (rate and severity of adverse events), and correlation of adverse events, such as peripheral sensory neuropathy (PSN), with the administration period of oxaliplatin, etc. Results: From November 2011 to August 2014 (34 months), 196 patients were enrolled. Safety was analyzed in 190 patients. The median total doses of capecitabine and oxaliplatin were 215,586.9 and 777.2 mg/m2, respectively, while the median relative dose intensities were 82.5 and 76.0%, respectively. The overall treatment completion rate was 73.7%. The most frequent treatment-related adverse event was PSN (88.4%), while the most frequent grade ≥3 treatment-related adverse events were neutropenia (12.6%), PSN (6.3%), diarrhea (4.2%), and thrombocytopenia (4.2%). There were no treatment-related deaths. Conclusions: Adjuvant XELOX is tolerable for Japanese patients with Stage III colon cancer.

AB - Purpose: Adjuvant oxaliplatin plus oral capecitabine (XELOX) is recommended for patients with curatively resected colon cancer. However, its safety and tolerability in Asian patients is unclear; therefore, we evaluated the safety and efficacy of adjuvant XELOX in Japanese patients with curatively resected stage III colon cancer (MCSCO-1024) and present the interim safety data. Methods: This prospective, multi-center, open-label, single-arm phase II study recruited patients with curatively resected stage III colon cancer. The protocol was a 120-min intravenous infusion of oxaliplatin (130 mg/m2) on day 1 and oral capecitabine (2000 mg/m2/day) in two divided doses for 14 days of a 3-week cycle, for a total of eight cycles (24 weeks). The primary endpoint was the 3-year disease-free survival, and secondary endpoints were the treatment completion rate, safety profile (rate and severity of adverse events), and correlation of adverse events, such as peripheral sensory neuropathy (PSN), with the administration period of oxaliplatin, etc. Results: From November 2011 to August 2014 (34 months), 196 patients were enrolled. Safety was analyzed in 190 patients. The median total doses of capecitabine and oxaliplatin were 215,586.9 and 777.2 mg/m2, respectively, while the median relative dose intensities were 82.5 and 76.0%, respectively. The overall treatment completion rate was 73.7%. The most frequent treatment-related adverse event was PSN (88.4%), while the most frequent grade ≥3 treatment-related adverse events were neutropenia (12.6%), PSN (6.3%), diarrhea (4.2%), and thrombocytopenia (4.2%). There were no treatment-related deaths. Conclusions: Adjuvant XELOX is tolerable for Japanese patients with Stage III colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=85027845718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027845718&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3419-1

DO - 10.1007/s00280-017-3419-1

M3 - Article

C2 - 28825216

AN - SCOPUS:85027845718

VL - 80

SP - 777

EP - 785

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -